Engineered proteins form the basis of biologic medicines, but traditional development is slow and costly. New AI tools now predict protein structures and interactions to identify viable drug candidates faster. This reduces the failure rate of candidates before they reach clinical trials. Researchers can now iterate molecular designs in silico.